8-K: Viemed Healthcare Reports Record Q3 2025 Revenue, Updates Guidance

Viemed Healthcare, Inc. announced record third-quarter 2025 financial results, driven by strong patient growth and strategic acquisition, while updating its full-year guidance.

Summary

• Net revenues for the quarter ended September 30, 2025, reached a Company record of $71.9 million, marking a 24.0% increase over the comparable quarter in 2024.
• Net income attributable to Viemed for Q3 2025 was $3.5 million, or $0.09 per diluted share.
• Adjusted EBITDA for Q3 2025 totaled $16.1 million, representing a 15.5% increase compared to Q3 2024.
• Net cash provided by operating activities was $18.4 million for the quarter and $48.5 million for the trailing twelve months ended September 30, 2025.
• Free cash flow amounted to $12.4 million for the quarter and $23.3 million for the trailing twelve months ended September 30, 2025.
• The strategic acquisition of Lehans Medical Equipment closed on July 1, 2025, and was immediately accretive to net income and earnings per share.
• During Q3 2025, the Company repurchased and cancelled 1,706,380 common shares at a cost of $11.4 million, with an average buyback price of $6.68 per share.
• Ventilator patient count increased to 12,372 as of September 30, 2025, an 8.8% increase year-over-year and a 1.8% sequential increase.
• PAP therapy patient count grew to 31,891 as of September 30, 2025, up 63.7% year-over-year and 21.4% sequentially.
• Sleep resupply patient count reached 33,518 as of September 30, 2025, an increase of 51.4% year-over-year and 32.8% sequentially.
• As of September 30, 2025, the Company maintained a cash balance of $11.1 million and an overall working capital balance of $5.8 million.
• Long-term debt as of September 30, 2025, was $19.6 million, with $38 million available under existing credit facilities.
• Full-year 2025 Net Revenue guidance was updated to a range of $271 million to $273 million (previously $271 million to $277 million).
• Full-year 2025 Adjusted EBITDA guidance was updated to a range of $60 million to $62 million (previously $59 million to $62 million).

Sentiment

Score: 7

Explanation: The company reported record revenues and strong patient growth, indicating robust operational execution. Strategic acquisition and share repurchases are positive capital deployment actions. However, the slight reduction in the upper end of revenue guidance and increased long-term debt warrant a balanced view, despite improved EBITDA outlook.

Positives

• Achieved record net revenues of $71.9 million in Q3 2025, a 24.0% increase year-over-year.
• Adjusted EBITDA increased by 15.5% to $16.1 million in Q3 2025.
• Generated strong net cash from operating activities ($18.4 million for Q3, $48.5 million for the trailing twelve months).
• Delivered significant free cash flow ($12.4 million for Q3, $23.3 million for the trailing twelve months).
• Successfully completed the strategic acquisition of Lehans Medical Equipment, which was immediately accretive to net income and EPS.
• Completed the 2025 share repurchase program, buying back 1,706,380 common shares for $11.4 million.
• Experienced sustained expansion of the patient base across all major service lines: vent patients up 8.8% YOY, PAP therapy patients up 63.7% YOY, and sleep resupply patients up 51.4% YOY.
• Maintained a strong liquidity position with an $11.1 million cash balance and $38 million available under credit facilities.
• Increased the lower end of the full-year 2025 Adjusted EBITDA guidance to $60 million (from $59 million).
• Higher-margin service lines, particularly Sleep, are tracking ahead of prior expectations, which is anticipated to enhance EBITDA margin.

Negatives

• Full-year 2025 Net Revenue guidance was narrowed to $271 million to $273 million, with the upper end reduced from the previous $277 million.
• Net income attributable to Viemed for Q3 2025 ($3.5 million) decreased compared to Q3 2024 ($3.878 million).
• Gross Profit percentage decreased to 57% in Q3 2025 from 59% in Q3 2024.
• Cash and cash equivalents decreased to $11.123 million as of September 30, 2025, from $17.540 million as of December 31, 2024.
• Working Capital decreased to $5.794 million as of September 30, 2025, from $15.554 million as of December 31, 2024.
• Long-term debt increased significantly to $19.585 million as of September 30, 2025, from $3.589 million as of December 31, 2024.
• Lower-margin services, including staffing, are now expected to grow slightly slower than previous forecasts.

Risks

• General business, market, and economic conditions in operating regions.
• Significant capital requirements and operating risks.
• Ability to implement business strategies and pursue business opportunities.
• Volatility in the market price of common shares.
• State of the capital markets and availability of funds and resources.
• Inflation.
• Reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities.
• Dependence on few payors.
• Possible new drug discoveries.
• Dependence on key suppliers.
• Granting of permits and licenses in a highly regulated business.
• Competition.
• Disruptions in or attacks (including cyber-attacks) on information technology, internet, network access or other voice or data communications systems or services.
• Evolution of various types of fraud or other criminal behavior.
• Difficulty integrating newly acquired businesses.
• Impact of new and changes to, or application of, current laws and regulations.
• Overall difficult litigation and regulatory environment.
• Increased funding costs and market volatility due to market illiquidity and competition for funding.
• Critical accounting estimates and changes to accounting standards, policies, and methods.
• Occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns.

Future Outlook

The company updated its full-year 2025 financial guidance, narrowing net revenue expectations to $271 million to $273 million (from $271 million to $277 million) and adjusting Adjusted EBITDA guidance to $60 million to $62 million (from $59 million to $62 million). This adjustment reflects increased visibility and a shift in growth expectations, with lower-margin services growing slower and higher-margin lines, particularly Sleep, tracking ahead of prior expectations, which is anticipated to enhance EBITDA margin.

Management Comments

• "We delivered another outstanding quarter marked by strong execution and sustained expansion of our patient base across every major service line."
• "Our disciplined approach to capital deployment was demonstrated through the full completion of our 2025 share repurchase program, while the acquisition of Lehans Medical Equipment further enhanced our market presence and diversified our service capabilities."
• "Both initiatives were accretive to earnings per share and reflect our unwavering commitment to creating long-term shareholder value while improving patient outcomes across the communities we serve."
• "Our strong liquidity and consistent free cash flow generation provide the flexibility to pursue strategic growth opportunities and return capital to shareholders, while preserving the financial strength that underpins our long-term success."

Industry Context

Viemed Healthcare operates in the growing in-home clinical care market for post-acute respiratory healthcare. The strong patient growth across ventilator, PAP therapy, and sleep resupply services aligns with broader industry trends favoring home-based care solutions, driven by cost-effectiveness, patient preference, and technological advancements. The strategic acquisition of Lehans Medical Equipment further consolidates its market position and diversifies service capabilities in a competitive but expanding sector.

Stakeholder Impact

• Shareholders: Positive impact due to share repurchase program (reducing outstanding shares, potentially increasing EPS), accretive acquisition, and strong free cash flow generation. Potential for long-term value creation.
• Patients: Continued expansion of patient base across service lines (ventilator, PAP therapy, sleep resupply) indicates improved access to in-home clinical care.
• Employees: Continued growth and strategic acquisitions may lead to job stability and potential expansion.
• Creditors: Increased long-term debt, but strong cash flow and available credit facilities suggest ability to manage obligations.

Next Steps

• Host a conference call to discuss third quarter results on Thursday, November 6, 2025, at 11:00 a.m. ET.
• An audio recording and transcript of the conference call will be accessible on the Company's website after the call.

Key Dates

Recommendation

While Viemed Healthcare demonstrated strong operational performance with record revenues, significant patient growth, and a strategic accretive acquisition, the slight downward adjustment to the upper end of full-year revenue guidance and the notable increase in long-term debt warrant a cautious approach. The improved Adjusted EBITDA outlook is positive, driven by a favorable shift in service mix, but the overall picture suggests a 'hold' as investors assess the impact of the revised revenue expectations and debt levels against the strong operational execution.

Keywords

Viemed Healthcare, VMD, Q3 2025 Earnings, Financial Results, Respiratory Healthcare, Home Care, Ventilators, Sleep Therapy, PAP Therapy, Adjusted EBITDA, Revenue Growth, Patient Growth, Share Repurchase, Acquisition, Lehans Medical Equipment, Guidance Update, Post-Acute Care, Medical Equipment, Healthcare Services